Waldenstrom Macroglobulinemia: Causes, Symptoms, and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Waldenstrom macroglobulinaemia (WM) is a rare, indolent lymphoproliferative B-cell malignancy classified as lymphoplasmacytic lymphoma (LPL) in the WHO Classification of Haematolymphoid Tumours, characterised by clonal infiltration of the bone marrow by lymphoplasmacytic cells and secretion of a monoclonal immunoglobulin M (IgM) paraprotein. Approximately 1,500-3,000 new cases are diagnosed per year in the United States, with a median diagnosis age of approximately 70 years. WM is slightly more common in males (approximately 3:2 male-to-female ratio) and in Caucasian patients, with higher familial incidence among first-degree relatives than in the general population. The disease exists on a continuum from the asymptomatic precursor state — IgM monoclonal gammopathy of undetermined significance (IgM MGUS, progressing to WM at approximately 1.5-2% per year) — through smouldering WM (asymptomatic WM meeting diagnostic criteria but not meeting treatment thresholds) to symptomatic WM requiring therapy. The molecular hallmark of WM is the MYD88 L265P somatic mutation, present in greater than 90% of WM cases and constitutively activating NF-kB survival signalling, which distinguishes WM from other IgM-secreting disorders and serves as the molecular target for BTK inhibitor therapy. WM is considered incurable with current therapies but is highly manageable with modern treatment, with median overall survival exceeding 10 years and quality of life maintained for many years.

The aetiology of WM involves a complex interplay of genetic predisposition, immune dysregulation, and acquired somatic mutations. IgM MGUS is the established precursor state: approximately 1.5-2% of IgM MGUS cases progress to WM per year, with predictors of progression including IgM level exceeding 1.5 g/dL, bone marrow lymphoplasmacytic infiltration above 5%, and presence of MYD88 L265P mutation. Familial WM and familial lymphoplasmacytic lymphoma clusters are well documented: first-degree relatives of WM patients have a significantly elevated risk of developing WM, other B-cell malignancies, and IgM MGUS, suggesting polygenic germline predisposition. Genome-wide association studies (GWAS) have identified risk loci on chromosomes 6p21.3 (HLA region), 14q32, and others. Chronic immune stimulation from hepatitis C virus (HCV) infection, Lyme disease borreliosis, and other chronic antigenic exposures may contribute to the emergence of WM clones in susceptible individuals; HCV eradication with direct-acting antivirals can reduce WM clone burden in some patients. Environmental factors including occupational pesticide exposure, organic solvent exposure, and prior radiotherapy have been associated with modestly elevated WM risk in case-control studies. At the molecular level, MYD88 L265P is a somatic gain-of-function mutation that constitutively activates TLR (Toll-like receptor) and IL-1 receptor signalling pathways, driving BTK (Bruton's tyrosine kinase) and IRAK4 phosphorylation, NF-kB nuclear translocation, and anti-apoptotic gene expression. Co-occurring CXCR4 mutations (present in approximately 30-40% of WM cases) activate SDF-1/CXCL12 signalling, enhance bone marrow homing of WM cells, and confer resistance to ibrutinib — making CXCR4 mutation testing clinically important for BTK inhibitor selection and dosing strategies.

WM produces symptoms through two main mechanisms: bone marrow infiltration by lymphoplasmacytic tumour cells causing cytopenias, and the pathological effects of the circulating monoclonal IgM paraprotein on various organ systems. Anaemia — from bone marrow infiltration, reduced erythropoiesis, and IgM-mediated haemolysis — is the most common symptom, causing progressive fatigue, dyspnoea on exertion, pallor, and reduced exercise tolerance; haemoglobin below 10 g/dL is a common treatment indication. Hyperviscosity syndrome occurs in approximately 15-30% of symptomatic WM patients when serum IgM exceeds approximately 3,000-4,000 mg/dL: the characteristic symptoms are headache, blurred vision or visual loss (from retinal haemorrhages visible on fundoscopy), dizziness, confusion, epistaxis, oral mucosal bleeding, and — in severe cases — stroke-like episodes with focal neurological deficits requiring emergency plasmapheresis. Peripheral neuropathy occurs in approximately 20-25% of WM patients as IgM deposits on myelin-associated glycoprotein (MAG), causing a slowly progressive, distal, predominantly sensory, 'length-dependent' neuropathy with disproportionate proprioceptive loss and gait ataxia; the IgM-anti-MAG neuropathy is a distinct and slowly progressive syndrome. Cold agglutinin haemolytic anaemia develops when IgM antibodies have specificity for the I blood group antigen on red blood cells, causing cold-triggered intravascular haemolysis. Cryoglobulinaemia from IgM with cryoprecipitating properties causes cold-induced Raynaud's phenomenon, acrocyanosis, skin ulceration, and glomerulonephritis. Hepatosplenomegaly and peripheral lymphadenopathy are present in a minority of patients. Constitutional B symptoms (fever, drenching night sweats, weight loss) are uncommon in indolent WM but may herald transformation to diffuse large B-cell lymphoma.

The diagnosis of WM requires the combination of a serum IgM monoclonal protein of any concentration and bone marrow infiltration by lymphoplasmacytic lymphoma of more than 10%, per the consensus diagnostic criteria established by the Second International Workshop on Waldenstrom's Macroglobulinaemia. Serum protein electrophoresis (SPEP) with immunofixation quantifies and characterises the IgM M-protein, distinguishing IgM from other immunoglobulin classes. Quantitative serum IgM level and serum viscosity measurement are essential for determining hyperviscosity risk. Bone marrow trephine biopsy with immunohistochemistry is the diagnostic cornerstone: WM cells are characteristically CD20+, CD19+, CD79a+, CD138+/-, surface IgM+, PAX5+, and are CD5-, CD10-, CD23- (distinguishing from mantle cell lymphoma and CLL). Allele-specific oligonucleotide PCR (ASO-PCR) or next-generation sequencing (NGS) for MYD88 L265P and CXCR4 mutation testing is recommended as standard at diagnosis for all patients — MYD88 mutation status confirms the WM diagnosis, while CXCR4 mutation status predicts ibrutinib response and guides selection of BTK inhibitor (zanubrutinib appears less affected by CXCR4 mutations than ibrutinib). CT of the chest, abdomen, and pelvis with IV contrast assesses adenopathy, hepatosplenomegaly, and extramedullary disease. The IPSSWM (International Prognostic Scoring System for WM) classifies patients into low, intermediate, and high-risk groups based on age, haemoglobin, platelet count, beta-2 microglobulin, and IgM level.

Asymptomatic (smouldering) WM requires observation without treatment: 'watch and wait' with monitoring of IgM level and haematological parameters every 3-6 months is the standard approach, as no trial has demonstrated benefit from pre-emptive treatment. Treatment initiation criteria include: symptomatic anaemia (Hgb less than 10 g/dL), symptomatic hyperviscosity, neuropathy, cold agglutinin haemolysis, cryoglobulinaemia, symptomatic organomegaly, or constitutional symptoms. First-line treatment for symptomatic WM is guided by molecular markers and patient characteristics. BTK inhibitors are the preferred first-line treatment for most patients with MYD88-mutated WM: ibrutinib (420 mg once daily, FDA-approved for WM) achieves overall response rates of approximately 90-100% in MYD88-mutated/CXCR4 wild-type patients; zanubrutinib (160 mg twice daily, FDA-approved) demonstrates improved tolerability over ibrutinib (ASPEN trial) with similar efficacy and better performance in CXCR4-mutated patients. Chemoimmunotherapy alternatives include: bendamustine plus rituximab (BR, highly effective with ORR approximately 90%); DRC (dexamethasone, rituximab, cyclophosphamide, monthly); and bortezomib-based regimens (BDR: bortezomib, dexamethasone, rituximab). Rituximab monotherapy is an option for low-disease-burden patients, but the IgM flare phenomenon requires caution in patients with high baseline IgM levels — plasmapheresis should precede rituximab in patients with IgM exceeding 4,000 mg/dL or those with symptomatic hyperviscosity to prevent acute IgM flare. Plasmapheresis (plasma exchange) is the emergency treatment for hyperviscosity syndrome, acutely removing approximately 70-80% of circulating IgM within a single 1-2 plasma volume exchange; it is temporising rather than curative and must be followed by cytoreductive therapy. Autologous SCT is considered for fit relapsed/refractory patients achieving at least a partial response to salvage therapy. Venetoclax and novel BTK degraders are in clinical investigation.

No established preventive measures have been proven to reduce the incidence of WM in the general population, given its complex polygenic aetiology and the sporadic nature of the initiating MYD88 somatic mutation in most cases. However, several management strategies for precursor states and risk factor mitigation are relevant. Individuals with IgM MGUS — particularly those with IgM greater than 1.5 g/dL, bone marrow infiltration on biopsy, or MYD88 L265P mutation — should receive structured surveillance with annual serum IgM measurement, full blood count, and clinical assessment, as they have the highest annual progression rates to symptomatic WM. First-degree relatives of WM patients should be counselled about their modestly elevated familial risk and should report symptoms of IgM-related disease — neuropathy, unexplained anaemia, cold-related symptoms, vision changes — promptly to their physician. HCV testing is recommended in patients with IgM MGUS or WM, and HCV eradication with direct-acting antiviral therapy should be pursued in HCV-positive patients, as viral eradication can reduce IgM clone burden in HCV-driven WM. Occupational exposure to agricultural pesticides and organic solvents should be minimised through appropriate protective equipment and regulatory compliance. For patients with established WM, avoidance of known triggers for hyperviscosity symptoms — including dehydration and significant cold exposure — reduces the risk of symptomatic viscosity crises between treatment cycles. Rituximab IgM flare prevention through pre-treatment plasmapheresis in high-IgM patients (IgM above 4,000 mg/dL) is an important clinical safety measure.

Seek urgent medical evaluation for symptoms that may indicate hyperviscosity syndrome, as this is a potentially life-threatening complication of WM. Red flag symptoms requiring same-day or emergency evaluation include: sudden visual disturbances or blurring in both eyes (retinal haemorrhage from hyperviscosity); severe headache, confusion, or focal neurological signs; unexplained epistaxis or mucosal bleeding not attributable to trauma; and stroke-like symptoms with slurred speech or unilateral weakness in a patient with known or suspected WM. Known WM patients who develop fever, rapidly worsening night sweats, weight loss, or sudden lymphadenopathy enlargement should seek prompt haematological assessment to exclude Richter's transformation to high-grade lymphoma. Patients taking ibrutinib or zanubrutinib who develop atrial fibrillation (palpitations, irregular heartbeat), major bruising, or bleeding should contact their haematology team urgently, as BTK inhibitor-associated atrial fibrillation and bleeding require immediate management. Unexplained progressive sensory symptoms — particularly bilateral leg tingling, numbness, or gait unsteadiness — in an older adult should prompt serum protein electrophoresis with immunofixation, as IgM-anti-MAG neuropathy may be the first presentation of WM. Fatigue and progressive dyspnoea on exertion in an older adult with no obvious cardiac or pulmonary explanation warrants a full blood count and serum protein electrophoresis. Individuals with known IgM MGUS should attend their scheduled annual surveillance visits without delay and report any new or changing symptoms between appointments.

WM is an indolent, treatable but not curable disease with median OS that has improved to over 10 years with modern BTK inhibitor and chemoimmunotherapy regimens. IPSSWM stratifies low, intermediate, and high-risk patients. Transformation to diffuse large B-cell lymphoma (Richter's transformation) occurs in approximately 2-10% and carries poor prognosis with median OS less than 12 months. Most patients maintain excellent quality of life for many years with intermittent or continuous treatment cycles. The prognosis for Waldenstrom Macroglobulinemia: Causes, Symptoms, and Treatment varies depending on severity at diagnosis, the patient's overall health, and how promptly treatment is initiated. With early diagnosis and appropriate management, many patients achieve good outcomes and maintain quality of life. Regular follow-up with healthcare providers is essential to monitor progress, adjust treatment as needed, and detect any complications early. Adherence to prescribed treatments and lifestyle modifications significantly improves long-term prognosis.